Literature DB >> 455329

Electron microscopic studies of the heart and light microscopic studies of the skin after treatment of golden hamsters with adriamycin, detorubicin, AD-32, and aclacinomycin.

D Dantchev, V Slioussartchouk, M Paintrand, M Hayat, C Bourut, G Mathé.   

Abstract

Golden hamsters received Adriamycin (ADR), detorubicin (DTR), AD-32, or aclacinomycin (ACM) three times weekly at doses extrapolated from optimal doses in L1210 leukemia. Minimal early lesions of the myocardium were detected by electron microscopy in ACM-treated animals. These lesions were aggravated after several weeks of treatment but remained reversible. Lesions in AD-32-treated hamsters were slightly more marked than those seen in ACM-treated animals but were much less severe than those observed in ADR- or DTR-treated animals. Similarly, light microscopy revealed pathologic changes in the skin following ADR or DTR administration. These changes were not seen in animals receiving AD-32 or ACM.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 455329

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  11 in total

1.  4'-O-tetrahydropyranyl adriamycin (THP-ADM)-induced modifications of murine peritoneal macrophages.

Authors:  A Bravo-Cuellar; G Mathé; S Orbach-Arbouys
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

2.  The multiplication of analogs, the best strategy for rapid extension of the oncostatic arsenal. How can they be compared experimentally?

Authors:  G Mathé; C Jasmin
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

3.  Comparison of acute effects of anthracyclines on cardiac electrophysiological parameters of isolated guinea-pig hearts.

Authors:  G Stark; U Stark; H Samonigg; K Kasparek; A Lueger; S Nagl; H Bertuch; E Pilger; H A Tritthart
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 4.  Antitumor antibiotics discovered and studied at the Institute of Microbial Chemistry.

Authors:  T Takeuchi
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

5.  Phase I trials in clinical oncostatic pharmacology.

Authors:  P Ribaud; G Mathé
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

6.  Salvage chemotherapy of refractory non-Hodgkin's lymphoma with aclacinomycin, behenoyl ara-C, etoposide, and prednisolone.

Authors:  T Yoshida; S Nakamura; S Ohtake; K Kobayashi; M Kanno; T Matsuda; S Matano; K Kondo; K Okafuji; M Kanai
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  Cellular pharmacokinetics of aclacinomycin A in cultured L1210 cells. Comparison with daunorubicin and doxorubicin.

Authors:  A Zenebergh; R Baurain; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  Phase II trial of aclacinomycin A in acute leukemia and various solid tumors.

Authors:  J Schütte; N Niederle; S Seeber
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

9.  Preliminary results of a phase II trial of aclacinomycin in acute leukaemia and lymphosarcoma. An oncostatic anthracyclin that is rarely cardiotoxic and induces no alopecia.

Authors:  G Mathé; M Bayssas; J Gouveia; D Dantchev; P Ribaud; D Machover; J L Misset; L Schwarzenberg; C Jasmin; M Hayat
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

10.  An in vivo and in vitro trial of aclarubicin in metastatic breast cancer: a novel approach to the study of analogs.

Authors:  R B Natale; R L Cody; M S Simon; R H Wheeler
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.